MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
Business Wire

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Isl…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Pharmabiz

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
Clinical Trials Arena on MSN

MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).